Clinical Evidence

ClinicalEVIDENCE Newsletter

Newsletter #1 – March 2024

March Issue

Welcome to the ClinicalEVIDENCE newsletter, your go-to source for the latest clinical data on heart diseases, diagnostics, and monitoring.

Our aim is to provide you with cutting-edge information that will keep you up to date on the most recent advancements in the field of heart failure management and sudden cardiac death prevention.


This Clinical Evidence delves into the most recent real-world data concerning the performance of the HeartLogic™ algorithm and S-ICD and their potential application in clinical practice to improve patient outcomes.  A new re-validation of the HeartLogic diagnostic tool¹ is explored in order to confirm the performance of the algorithm in clinical practice for implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy devices (CRT-D). S-ICD clinical experiences from two retrospective analyses from the observational Rhythm Detect registry are described. One analysis assesses the enhanced outcomes associated with placing the S-ICD generator in the intermuscular space²; the other investigates the decrease in inappropriate therapies through device programming³.

Key Takeaways

  1. HeartLogic Algorithm: Real-World Validation:
    HeartLogic performances were validated in a real-world setting: high performance in terms of sensitivity and false positive rate were confirmed for ICD and CRT-D patients¹.
  2. S-ICD Performance in Real-World Practice 1:
    Placing the S-ICD generator in the intermuscular space instead of the standard subcutaneous pocket results in fewer device-related complications and inappropriate shocks over a medium-term follow-up² .
  3. S-ICD Performance in Real-World Practice 2:
    In clinical practice, there has been a trend in recent years towards the wider adoption of optimized programming. The standardised programming proposed by the UNTOUCHED study reduced the rate of inappropriate shock in the S-ICD population, without affecting therapy effectiveness³.

Gain deeper insights by downloading the full newsletter

Stimview XT data driven brochure


Newsletter 2024 #1
Now Available in PDF Format


  1. Singh JP, Wariar R, Ruble S, et al. Prediction of Heart Failure Events With the HeartLogic Algorithm: Real-World Validation. J Card Fail. 2023;S1071-9164(23) 00868-0.
  2. Botto GL, Ziacchi M, Nigro G, et al. Intermuscular technique for implantation of the subcutaneous implantable defibrillator: a propensity-matched case-control study. Europace. 2023;25(4):1423–1431.
  3. Rordorf R, Viani S, Biffi M, et al. Reduction in inappropriate therapies through device programming in subcutaneous implantable defibrillator patients: data from clinical practice. Europace. 2023;25(5):euac234.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. ©2024 Boston Scientific Corporation or its affiliates. All rights reserved.